Randomized Phase 3 Trial of Gemcitabine/Carboplatin With or Without Iniparib (SAR240550) (a PARP1 Inhibitor) in Subjects With Previously Untreated Stage IV Squamous Non-Small-Cell Lung Cancer (NSCLC).

Trial Profile

Randomized Phase 3 Trial of Gemcitabine/Carboplatin With or Without Iniparib (SAR240550) (a PARP1 Inhibitor) in Subjects With Previously Untreated Stage IV Squamous Non-Small-Cell Lung Cancer (NSCLC).

Completed
Phase of Trial: Phase III

Latest Information Update: 27 Aug 2014

At a glance

  • Drugs Iniparib (Primary) ; Carboplatin; Gemcitabine
  • Indications Non-small cell lung cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms ECLIPSE
  • Sponsors Sanofi
  • Most Recent Events

    • 03 Jun 2013 Primary endpoint 'Overall-survival-rate' has not been met, according to a Sanofi media release.
    • 03 Jun 2013 Status changed from active, no longer recruiting to completed.
    • 03 Jun 2013 Top-line results reported in a Sanofi media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top